Bicycle Therapeutics Narrows Q2 Loss, Extends Cash Runway to 2030
BCYC is trading near its 52-week low of $3.85 (0.8% below the low).
Summary
Bicycle Therapeutics reported a narrower Q2 net loss of $50.3M, down from the prior year, driven by reduced clinical program and personnel costs following a workforce reduction. Collaboration revenue fell sharply year-over-year, but the company now expects its cash runway to extend into 2030, a significant improvement. The pipeline remains active with a Phase 1 trial for BT1702 on track for 2027 and ongoing enrollment in a Phase 2 pancreatic cancer study. This follows the termination of the Bayer collaboration, which will trigger a $33.2M revenue recognition in Q3. The stock trades near its 52-week low, making the extended runway and cost discipline a potential positive catalyst for sentiment.
At the time of this announcement, BCYC was trading at $3.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $269.1M. The 52-week trading range was $3.85 to $9.16. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.